证券代码：002349 证券简称：精华制药 公告编号：2023-028 精华制药集团股份有限公司 第五届董事会第十七次次会议决议公告 表决结果：7票赞成；0票弃权；0票反对。 3、审议通过了《关于续聘会计师事务所的议案》。 《关于续聘会计师事务所的公告》详见《证券时报》、巨潮资讯网 (www.cninfo.com.cn)。该议案尚需提交股东大会审议。 本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中的虚假记载、 误导性陈述或者重大遗漏承担责任。 精华制药集团股份有限公司（以下简称"公司"、"本公司"、"精华制药"） 第五届董事会第十七次会议通知于2023年10月15日以传真、专人送达、邮件等形式 发出，会议于2023年10月26日（星期四）以通讯和现场相结合的方式在公司会议室 召开。公司部分监事、高级管理人员列席了会议，会议的召开符合《中华人民共和 国公司法》及《公司章程》的有关规定，会议的召集、召开合法有效。会议由董事 长尹红宇先生主持。 本次会议审议了以下议案： 1、审议通过了《2023年第三季度报告》。 《2023年第三季度报告》详见《证券时报》、巨潮资讯网(www.cninfo.com. ...

证券代码：002349 证券简称：精华制药 公告编号：2023-029 精华制药集团股份有限公司 第五届监事会第十二次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确和完整，并对公告中的虚假记 载、误导性陈述或者重大遗漏承担责任。 精华制药集团股份有限公司（以下简称"公司"）第五届监事会第十二次会议 通知于2023年10月15日以传真、专人送达、邮件等形式发出，会议于2023年10 月26日（星期四）以通讯和现场相结合的方式在公司会议室召开。会议应出席监 事3名，出席监事3名，会议的召开符合《中华人民共和国公司法》及《公司章程》 的有关规定，会议的召集、召开合法有效。会议由监事会主席薛红卫先生主持。 2023 年 10 月 30 日 本次会议审议通过了以下议案： 1、审议通过了《2023年第三季度报告》。 经过对公司2023年第三季度报告进行全面的审核后，监事会认为董事会编制 和审核公司2023年第三季度的程序符合法律、行政法规和中国证监会的相关规定， 报告内容真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、误 导性陈述或者重大遗漏。 表决结果：3票赞成；0票弃权；0票反对。 特此公告。 ...

证券代码：002349 证券简称：精华制药 公告编号：2023-030 精华制药集团股份有限公司 关于续聘会计师事务所的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中的虚假记载、 误导性陈述或者重大遗漏承担责任。 精华制药集团股份有限公司（以下简称"公司"）于2023年10月26日召开第五 届董事会第十七次会议审议通过了《关于续聘会计师事务所的议案》，本次续聘会 计师事务所事项尚需提交股东大会审议，具体情况如下： 一、机构信息 天衡会计师事务所（特殊普通合伙）前身为始建于 1985 年的江苏会计师事务 所，1999 年脱钩改制，2013 年转制为特殊普通合伙会计师事务所。注册地址为江 苏省南京市建邺区江东中路 106 号 1907 室，经营范围为审查企业会计报表，出具 审计报告；验证企业资本，出具验资报告；办理企业合并、分立、清算事宜中的审 计业务，出具有关报告；基本建设年度财务决算审计；代理记账，会计咨询、税务 咨询、 管理咨询、会计培训。（依法须经审批的项目，经相关部门批准后方 可开 展经营活动） 2022 年末，天衡会计师事务所已提取职业风险基金 1,656.56 万元，购买的职 ...

证券代码：002349 证券简称：精华制药 公告编号：2023-027 精华制药集团股份有限公司 关于公司股东减持股份完成的公告 股东南通综艺投资有限公司、江苏综艺控股集团有限公司、昝圣达先生保证向本公司 提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 精华制药集团股份有限公司（以下简称"公司"或"本公司"）于2023年3月18 日披露了《关于持股5%以上股东减持股份计划的预披露公告》，具体内容详见 《证券时报》、巨潮资讯网(www.cninfo.com.cn)。公司股东南通综艺投资有限公 司（以下简称"综艺投资"）、昝圣达先生拟自2023年4月11日起的6个月内通过 证券交易所集中竞价交易方式减持公司股份不超过16,283,618股（不超过公司总 股份的2%），且任意连续90日内减持股份的总数不超过公司总股本的1%。 近日，公司收到综艺投资、江苏综艺控股集团有限公司（以下简称"综艺控 股"）、昝圣达先生减持计划完成的告知，其减持计划已完成。本次减持计划完 成情况具体内容如下： 一、已披露的减持计划主要内容 本次减持前， ...

证券代码：002349 证券简称：精华制药 | --- | --- | --- | |----------------|---------------|-------------| | 投资者关系活动 | √特定对象调研 | □分析师会议 | | 类别 | □媒体采访 | □业绩说明会 | | | | | | | □新闻发布会 | □路演活动 | □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及 人员姓名 西部证券 丁健行 时间 15：00-16：00 地点 线上 上市公司接待人 董事会秘书 王剑锋 员姓名 证券事务代表 樊屹秋 主要介绍公司半年度报告业绩情况，以及公司主要产品。 投资者关系活动 主要内容介绍 附件清单（如有） 无 日期 2023 年 8 月 28 日 精华制药集团股份有限公司投资者关系活动记录表 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥795,349,522.37, representing a 0.48% increase compared to ¥791,546,445.79 in the same period last year[24]. - The net profit attributable to shareholders increased by 18.85% to ¥154,607,331.58 from ¥130,082,099.19 year-on-year[24]. - The net profit after deducting non-recurring gains and losses rose by 24.86% to ¥150,284,938.85 compared to ¥120,363,373.59 in the previous year[24]. - The basic earnings per share increased by 18.84% to ¥0.1899 from ¥0.1598 in the same period last year[24]. - The total assets at the end of the reporting period were ¥3,071,370,283.37, a 0.98% increase from ¥3,041,677,568.76 at the end of the previous year[24]. - The net assets attributable to shareholders increased by 3.78% to ¥2,491,664,487.10 from ¥2,400,966,083.66 at the end of the previous year[24]. - The net cash flow from operating activities decreased by 30.02% to ¥99,763,312.02 from ¥142,554,001.49 in the same period last year[24]. - The weighted average return on equity increased to 6.24% from 5.65% year-on-year[24]. - The company achieved consolidated sales revenue of CNY 795.35 million, a year-on-year increase of 0.48%[43]. - The net profit attributable to the parent company was CNY 155 million, representing a year-on-year growth of 18.85%[43]. - Operating cash flow net amount was CNY 99.76 million, a decrease of 30.02% compared to the previous year[49]. - Research and development investment decreased by 14.96% to CNY 28.78 million[49]. - Sales expenses increased by 3.89% to CNY 107.72 million, while management expenses decreased by 22.10% to CNY 52.83 million[49]. - The company reported a total revenue of 4,322,392.73, with a significant portion attributed to non-operating income[29]. Product and Market Development - The main business activities include the R&D, production, and sales of traditional Chinese medicine, chemical raw materials, and biopharmaceuticals[32]. - Key products include Wang's Baorichuan Pill, which is used for various digestive and respiratory issues, and has been recognized in multiple medical guidelines[36][38]. - The company has a unique product advantage with proprietary formulas for its key products, including Wang's Baorichuan Pill and Jide Sheng Snake Medicine Tablet, which are classified as state secrets[36][37]. - The company emphasizes a vertically integrated business model, enhancing growth through internal management and expanding its presence across the pharmaceutical supply chain[39]. - The company is actively involved in the development of new products and technologies to enhance its market position[39]. - The company is actively promoting the "going out" strategy for traditional Chinese medicine, with successful registration in Macau[43]. - The company has obtained European COS certification for five products, and several products have passed FDA on-site audits[41]. - The company completed the registration of a new product, Huberzong, in 19 European countries, with nearly 6 tons of commercial orders obtained[44]. - The company has established a 30,000-acre organic Chinese medicinal herb planting base in Gansu Province, contributing to local employment by hiring 71 people and purchasing local medicinal materials worth 25.9844 million yuan[123]. - The company has conducted three training sessions for over 150 participants on organic planting techniques for traditional Chinese medicinal herbs, enhancing local farmers' income and preventing poverty recurrence[123]. - The company is committed to investing in local organic medicinal herb cultivation and processing, aligning with local government rural revitalization efforts[123]. Environmental and Safety Compliance - The company adheres to strict environmental standards for emissions and waste management across its subsidiaries[80]. - The company has obtained the latest pollutant discharge permit, valid until March 12, 2028[84]. - The company’s wastewater and air emissions have passed self-inspection, with solid waste and noise approved by the local environmental protection bureau[85]. - The company’s first phase project completed environmental protection acceptance in April 2022, and the discharge permit was obtained in February 2022[87]. - The company’s wastewater discharge concentration for COD is 233.574 mg/l, below the standard limit of 500 mg/l[88]. - The company has established wastewater treatment facilities with automatic monitoring equipment to ensure compliance with discharge standards[92]. - The company has implemented various pollution discharge standards, including those for volatile organic compounds and wastewater[83]. - The company has a comprehensive waste management strategy, including the treatment of solid waste and sludge through authorized channels[94]. - The company has a dedicated safety and environmental management department to oversee compliance with safety and environmental regulations[104]. - The company conducts regular monitoring of wastewater and air emissions, including online monitoring every two hours for wastewater[105]. - The company has conducted emergency drills to enhance employees' capabilities in handling environmental incidents[104]. - The company’s environmental emergency response plan was reviewed and approved in July 2022[103]. Shareholder and Financial Management - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[5]. - The company has distributed a total cash dividend of 147 million yuan from 2021 to 2023, emphasizing its commitment to shareholder returns[118]. - The company has not reported any non-compliance issues or financial irregularities during the reporting period[126][127][128]. - The company reported a significant increase in sales to related parties, with actual sales amounting to CNY 97,500 (approximately USD 14,000) during the reporting period[134]. - The company has a total of CNY 29.9 million (approximately USD 4.2 million) in entrusted financial management products, all of which are bank financial products with no overdue amounts[147]. - The total number of ordinary shareholders at the end of the reporting period is 142,450[156]. - The largest shareholder, Nantong Industrial Holding Group, holds 34.39% of the shares, totaling 279,994,660 shares[156]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period[160]. Future Outlook and Strategic Initiatives - The company plans to expand its market presence by entering three new regions by the end of 2024[194]. - A new product line is expected to launch in Q4 2023, which is anticipated to contribute an additional 300 million yuan in revenue[194]. - The company is exploring potential acquisitions to enhance its product portfolio and market share[194]. - The company has set a performance guidance of 2.2 billion yuan in revenue for the next half of the year, indicating a growth target of 15%[193]. - The company has initiated a strategic partnership with a leading biotech firm to enhance its product pipeline and accelerate development timelines[197]. - The company aims to improve shareholder value through effective capital management strategies[200].

关于第五届董事会第十六次次会议相关议案的 精华制药集团股份有限公司独立董事 独立意见 根据《关于在上市公司建立独立董事制度的指导意见》、《深圳证券交易所 关于上市公司内部审计工作指引》、《上市公司规范运作指引》及《公司独立董 事工作制度》等相关规定，作为精华制药集团股份有限公司（下称"公司"）独立 董事，已于会前认真审阅了公司第五届董事会第十六次会议的相关议案材料，经 审慎分析，发表如下独立意见： 一、累计和当期对外担保及关联方占用资金情况的独立意见 （1）公司不存在控股股东及其他关联方非正常项占用公司资金的情况； （2）截至 2023 年 6 月 30 日，公司不存在对外担保事项。 独立董事：王煦、冯巧根、马玲 二〇二三年八月二十四日 ...

精华制药集团股份有限公司 2023年半年度非经营性资金占用及其他关联资金往来情况汇总表 | 单 位 人 民 币 万 元 ： 来 来 来 来 来 来 来 来 来 来 来 来 来 来 | 。 | 非 现 其 其 大 上 子 其 及 [ 丝 | | --- | --- | --- | | 2 023 年 半 2 023 年 半 2 023 年 半 上 上 占 用 方 与 市 公 司 核 2 023 年 期 初 年 度 占 用 累 2 023 年 半 经 营 性 资 年 度 占 用 资 年 度 度 偿 还 资 金 占 用 方 名 称 市 公 司 的 关 算 的 会 计 科 占 用 资 金 余 计 发 生 金 额 年 度 期 末 占 占 用 形 成 原 因 占 用 性 质 金 金 息 生 金 占 用 的 利 累 计 发 联 关 系 目 额 （ 不 含 利 用 资 金 余 额 （ 如 有 ） 额 息 ） 大 股 东 及 - - - - - - - - - - 附 属 企 业 小 计 - - - - - - - - - - 2 023 年 半 2 023 年 半 上 上 往 来 方 与 市 公 司 核 2 023 年 期 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 416,357,917.91, representing a 1.87% increase compared to CNY 408,730,383.60 in the same period last year[5] - Net profit attributable to shareholders increased by 31.14% to CNY 87,671,328.30 from CNY 66,855,252.60 year-on-year[5] - The net profit after deducting non-recurring gains and losses rose by 37.56% to CNY 85,573,376.48 compared to CNY 62,208,068.96 in the previous year[5] - The company's basic and diluted earnings per share increased by 31.18% to CNY 0.1077 from CNY 0.0821 in the same quarter last year[5] - Net profit for Q1 2023 was CNY 99,041,270.14, compared to CNY 74,853,545.20 in the same period last year, indicating an increase of approximately 32.16%[19] - The net profit attributable to the parent company for Q1 2023 was ¥87,671,328.30, an increase of 31.1% compared to ¥66,855,252.60 in Q1 2022[20] - The total comprehensive income for the parent company was ¥87,671,328.30, up from ¥66,855,252.60, reflecting a growth of 31.1% year-over-year[20] - Basic and diluted earnings per share for Q1 2023 were both ¥0.1077, compared to ¥0.0821 in the same period last year, representing a 31.1% increase[20] Assets and Liabilities - Total assets at the end of Q1 2023 were CNY 3,091,955,034.11, a 1.65% increase from CNY 3,041,677,568.76 at the end of the previous year[5] - Total assets amounted to CNY 3,091,955,034.11, up from CNY 3,041,677,568.76, indicating a growth of about 1.65%[17] - Total liabilities decreased to CNY 367,934,315.21 from CNY 417,934,051.11, a reduction of approximately 11.97%[17] Cash Flow - The company's cash flow from operating activities turned negative at CNY -5,318,150.98, a decline of 110.85% compared to CNY 49,036,733.84 in the same period last year[5] - Cash inflow from operating activities totaled ¥335,773,634.65, down from ¥397,627,479.43 in Q1 2022, indicating a decrease of 15.6%[23] - The net cash flow from operating activities was negative at -¥5,318,150.98, compared to a positive ¥49,036,733.84 in the previous year[23] - Cash inflow from investment activities was ¥52,212,131.92, a decrease of 60.5% from ¥132,045,365.89 in Q1 2022[23] - The net cash flow from investment activities was -¥5,548,102.56, compared to -¥35,780,083.95 in the same period last year, showing an improvement[23] - The net cash flow from financing activities was -¥233,372.22, compared to -¥63,737,246.56 in Q1 2022, indicating a significant reduction in cash outflow[23] - The total cash and cash equivalents decreased by ¥12,937,676.99 during the quarter, compared to a decrease of ¥50,824,863.51 in the previous year[23] Receivables and Payables - The company reported a significant increase in accounts receivable by 72.08%, reaching CNY 39,301,314.34 due to an increase in bank notes received[9] - Other receivables rose by 54.58% to CNY 4,178,705.94, attributed to increased receivables from a subsidiary[9] - Accounts receivable increased to CNY 260,391,030.56 from CNY 219,069,324.58, marking an increase of about 18.87%[16] - The company experienced a 45.86% decrease in contract liabilities, down to CNY 24,416,332.85, due to reduced pre-sales[9] Expenses - Total operating costs decreased to CNY 298,578,026.85 from CNY 317,954,488.35, reflecting a reduction of about 6.06%[19] - The company reported a decrease in selling expenses to CNY 47,267,598.34 from CNY 58,811,849.14, a decline of about 19.66%[19] - Research and development expenses were CNY 13,215,026.76, down from CNY 14,784,119.29, representing a decrease of approximately 10.59%[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 148,231, with no preferred shareholders[12] - The largest shareholder, Nantong Industrial Holdings Group Co., Ltd., holds 34.39% of the shares, totaling 279,994,660 shares[12] Other Financial Metrics - The company recorded a 54461.01% increase in non-operating income, amounting to CNY 422,029.41, due to higher income unrelated to daily operations[9] - The company reported a 71.93% increase in tax payments, totaling CNY 53,233,443.50, due to reduced tax deferral benefits from the previous year[10] - Cash received from investment decreased by 60.41% to CNY 51,900,000.00, attributed to fewer maturing financial products compared to the same period last year[10] - The company reported a 71.98% decrease in cash received from investment income, totaling CNY 259,331.92, due to fewer maturing financial products[10] - Cash flow from the disposal of fixed assets increased by 230.00% to CNY 52,800.00, driven by more asset disposals by a subsidiary[10] - The company did not receive any cash from borrowings during the reporting period, marking a 100% decrease compared to the previous year[10] - The impact of exchange rate fluctuations on cash and cash equivalents was a negative CNY 1,838,051.23, reflecting significant currency volatility[10] Audit Information - The company did not conduct an audit for the Q1 2023 report[25]

Financial Performance - The company's operating revenue for 2022 was ¥1,573,059,814.20, representing a 15.85% increase compared to ¥1,357,868,013.63 in 2021[22] - The net profit attributable to shareholders for 2022 was ¥212,232,945.44, a 32.07% increase from ¥160,702,159.91 in 2021[22] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥175,758,751.94, up 34.00% from ¥131,160,407.17 in 2021[22] - The basic earnings per share for 2022 was ¥0.2607, reflecting a 32.07% increase from ¥0.1974 in 2021[22] - The total assets at the end of 2022 were ¥3,041,677,568.76, a decrease of 4.89% from ¥3,198,096,241.82 at the end of 2021[22] - The net assets attributable to shareholders at the end of 2022 were ¥2,400,966,083.66, an increase of 7.39% from ¥2,235,838,542.50 at the end of 2021[22] - The cash flow from operating activities for 2022 was ¥358,389,891.67, which is a 17.29% increase compared to ¥305,570,854.59 in 2021[22] - The weighted average return on equity for 2022 was 9.15%, up from 7.40% in 2021, indicating improved profitability[22] Revenue Breakdown - In 2022, the company's total revenue for the four quarters was approximately CNY 1.57 billion, with the highest revenue in Q1 at CNY 408.73 million and the lowest in Q3 at CNY 383.48 million[26] - The pharmaceutical manufacturing sector contributed ¥1,429,839,367.4, accounting for 90.90% of total revenue, with a growth of 14.79% year-on-year[67] - The international revenue increased significantly by 39.47%, amounting to ¥169,267,776.00, compared to ¥121,362,809.22 in the previous year[67] Product Development and Innovation - The company launched 9 new invention patents and 14 utility model patents in 2022, focusing on innovative drug development[64] - The company has completed the development of a new product based on the classic Chinese medicine formula, which is expected to create new economic growth points[77] - The company initiated clinical trials for several new drugs, including Wang's Baohong Pill for treating infant digestive disorders[64] - The company has established a talent development plan, enhancing its workforce through competitive recruitment and performance evaluation mechanisms[65] Market Strategy and Expansion - The company plans to enhance its product offerings by collaborating with third-party organizations for further development and expanding the indications of its proprietary TCM products[36] - The company is actively expanding its product offerings, with plans to enter the U.S. market with products like Pumice and has made breakthroughs in the sales of Dimethylhydrazine[60] - The company aims to enhance market control by developing both hospital and pharmacy channels, aiming for integrated online and offline operations[99] Risk Management - The company has identified risks related to raw material procurement, sales price declines, and product quality, which are discussed in the management's outlook section[4] - The National Medical Products Administration has intensified regulatory compliance requirements, urging the company to strengthen its drug safety monitoring systems[42] Corporate Governance - The company maintains complete independence in assets, personnel, finance, institutions, and business operations, ensuring no reliance on controlling shareholders[108] - The financial department operates independently with dedicated personnel, adhering to accounting standards and maintaining separate bank accounts from shareholders[109] - The company has established a strong governance structure with a mix of experienced professionals in key management positions, which is crucial for future growth and market expansion[119] Environmental Compliance - The company has complied with environmental protection standards, including air and water pollution discharge standards[150] - The company is classified as a key pollutant discharge unit by environmental protection authorities[150] - The company has established automatic monitoring devices for both wastewater and air emissions, ensuring compliance with environmental standards[171] Social Responsibility - The company invested 38.8629 million yuan in local medicinal materials procurement, creating 70 jobs in Longxi County, which transitioned from a national poverty-stricken county to a development stage in 2019[193] - The company conducted training sessions for over 300 participants on organic planting techniques for local medicinal materials, contributing to rural revitalization efforts[194] - The company donated 5,000 yuan to support rural revitalization in Zhengjiaping Village, Longxi County, demonstrating its commitment to social responsibility[194]